Literature DB >> 7201400

Behavioural and biochemical changes following chronic administration of L-dopa to rats.

C Pycock, D Dawbarn, C O'Shaughnessy.   

Abstract

Rats were given powdered diet containing L-DOPA (together with the peripheral decarboxylase inhibitor carbidopa) for a period of 6 months. The estimated daily intake was in the range 20-30 mg/kg. Initially, at 1 week and 1 month, L-DOPA-fed rats exhibited enhanced spontaneous locomotor activity, but this fell to within the control range by 3 and 6 months, although (+)-amphetamine-induced hyperactivity was greater at 6 months in L-DOPA-treated animals than in control rats. Six months after receiving L-DOPA in their diet rats showed enhanced stereotypy scores to a series of dopamine agonists administered acutely including (+)-amphetamine, nomifensine, L-DOPA, apomorphine and piribedil compared with the control animals. In another behaviour test L-DOPA administration reduced the cataleptic potency of both fluphenazine and haloperidol was increased. Biochemically 6 months treatment of rats with L-DOPA was associated with significantly increased plasma concentrations of L-DOPA, enhanced striatal levels of L-DOPA, dopamine and dopamine metabolites, enhanced specific binding (as indicated by increased Bmax values) of [3H] spiroperidol, [3H] ADTN and [3H] 5-HT to striatal membranes, and increased basal and dopamine-stimulated striatal adenylate cyclase activity. The results are discussed in the light of changes of sensitivity of cerebral dopamine receptors, an increase in receptor numbers, and the tolerance to L-DOPA which often develop in the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201400     DOI: 10.1016/0014-2999(82)90626-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

Review 1.  Role of nitric oxide on motor behavior.

Authors:  E A Del Bel; F S Guimarães; M Bermúdez-Echeverry; M Z Gomes; A Schiaveto-de-souza; F E Padovan-Neto; V Tumas; A P Barion-Cavalcanti; M Lazzarini; L P Nucci-da-Silva; D de Paula-Souza
Journal:  Cell Mol Neurobiol       Date:  2005-03       Impact factor: 5.046

2.  Chronic levodopa impairs the recovery of dopamine agonist-induced rotational behavior following neural grafting.

Authors:  D M Yurek; K Steece-Collier; T J Collier; J R Sladek
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

3.  Long-term depletion of histamine in guinea-pigs by administration of alpha-fluoromethylhistidine, a specific inhibitor of histidine decarboxylase; effect on the sensitivity of histamine receptors.

Authors:  H Fukuda; K Maeyama; Y Ito; T Watanabe; H Wada
Journal:  Agents Actions       Date:  1988-06

4.  Chronic L-dopa treatment of rats and mice does not change the sensitivity of post-synaptic dopamine receptors.

Authors:  D M Jackson; O F Jenkins; R Malor; M J Christie; P Gregory
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-12       Impact factor: 3.000

5.  L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

Authors:  M Guttman; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

6.  The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats.

Authors:  K Voith
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys.

Authors:  L J Porrino; R S Burns; A M Crane; E Palombo; I J Kopin; L Sokoloff
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

8.  Pharmacological characterisation of spontaneous or drug-associated purposeless chewing movements in rats.

Authors:  N M Rupniak; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 9.  Acute dystonia induced by neuroleptic drugs.

Authors:  N M Rupniak; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.